Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner - Bułdak, Łukasz; Machnik, Grzegorz; Bułdak, Rafał Jakub; Łabuzek, Krzysztof; Bołdys, Aleksandra; Belowski, Dariusz; Basiak, Marcin; Okopień, Bogusław (Pharmacological reports, 2016)
Keywords: Anti-Inflammatory Agents - pharmacology; Atherosclerosis; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases - metabolism; Diabetes; Diabetes Mellitus, Type 2 - metabolism; Drug Safety and Pharmacovigilance; Exenatide; Glucagon-Like Peptide 1 - agonists; Humans; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Interleukin-10 - metabolism; Interleukin-1beta - metabolism; Lipopolysaccharides - pharmacology; Macrophage; Macrophages - drug effects; Macrophages - metabolism; Monocytes - drug effects; Monocytes - metabolism; Nitric Oxide Synthase Type II - metabolism; Original Research Article; Peptides - pharmacology; Pharmacotherapy; Pharmacy; Proto-Oncogene Proteins c-akt - metabolism; Tumor Necrosis Factor-alpha - metabolism; Venoms - pharmacology; Inflammation; Diabetes; Exenatide; Atherosclerosis; Macrophage